Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03662997
Other study ID # MxBFlex02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 19, 2019
Est. completion date November 15, 2019

Study information

Verified date January 2020
Source Molnlycke Health Care AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, randomized, controlled clinical trial (RCT) using a cross-over (repeated measures) design to evaluate safety and efficacy of three foam wound dressings in the local management of chronic wounds.


Description:

The study will be conducted in an outpatient setting of an academic clinical center over a total period of four weeks (28 days, -1/+2). The aim of this RCT is to evaluate and compare three different foam dressings in the local management of chronic wounds (i.e. venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs)) in an outpatient setting. A bordered, five-layer, flexible foam dressing with soft silicone adhesive technology will be evaluated versus a hydropolymer, adhesive foam island dressing and a multi-layered, hydrocellular foam dressing with silicone adhesive, within three focus areas; efficacy and safety of the dressings, participant-centric outcomes and health economic evaluation. Note: The terms used within the body of this report and results, in both the Primary and Secondary Outcomes, are defined as follows: Period 1: Weeks 1 and 2 of study follow-up visits. Period 2: Weeks 3 and 4 of study follow-up visits. Week 1: Designates data captured only on visit days 7 and 21. Week 2: Designates data captured only on visit days 14 and 28. During Week 1: Designates data captured on visit days 3, 7, 17 and 21. During Week 2: Designates data captured on visit days 10, 14, 24 and 28. Day 3 of Week 1 from tables: inclusive of data captured on Visit Days 3 and 17. Day 3 of Week 2 from tables: inclusive of data captured on Visit Days 10 and 24. Day 7 of Week 1 from tables: inclusive of data captured on Visit Days 7 and 21. Day 7 of Week 2 from tables: inclusive of data captured on Visit Days 14 and 28.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date November 15, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Male and female subjects 18-85 years of age with leg and foot ulcers (i.e. VLU, DFU). 2. Signed informed consent. 3. Subject and/or caregiver must be willing and able to tolerate multi-layered compression bandages when applicable and offloading footwear. 4. Study subject must be available and able to visit the clinic weekly for the full 4-week period. Exclusion Criteria: 1. Pressure ulcers should not be included. Pressure injury as defined by the National Pressure Ulcer Advisory Panel (NPUAP). 2. Presence of local wound infection as determined by study doctor based on clinical signs and symptoms. 3. Subject has any evidence of peripheral arterial disease (PAD). 4. Subject diagnosed with malignancy other than cutaneous basal cell carcinoma. 5. Subject has received growth factor therapy (e.g. autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix e.g. amnion, amniotic tissue) within 2 weeks of screening date. 6. Pregnancy or lactation at time of study participation. 7. Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization. 8. Subject is currently enrolled or participated in another investigational device, drug or biological trial within 30 days of baseline of this study. 9. Present history of alcohol or drug abuse. 10. Known allergy/hypersensitivity to any of the components of the dressing. 11. Subject not suitable for the investigation according to the investigator's judgment.

Study Design


Intervention

Device:
Bordered Five-Layer Foam Dressing
Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
Hydropolymer Foam Dressing
Hydropolymer, adhesive foam island dressing
Hydrocellular Multi-Layer Foam Dressing
Multi-layered, hydrocellular foam dressing with silicone adhesive

Locations

Country Name City State
United States Center for Clinical Research, Inc. Castro Valley California
United States Vascular and Wound Care Center Newark New Jersey
United States SerenaGroup Pittsburgh Pennsylvania
United States SerenaGroup Research Foundation Pittsburgh Pennsylvania
United States Center for Clinical Trials, Inc. San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Molnlycke Health Care AB

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary % of Participants With Equal or Better Rate of Dressing Durability Dressing strike-through determined @ Wk1 Day 3&7, and Wk3 Day 17&21. Dressing strike-through that occurred Day 3 and/or 7, Day 17 and/or 21 were included in final dataset.
Contributing factors to strike-through:
Saturation of dressing pad:
Inappropriate dressing type
Inappropriate dressing change freq. (i.e. more frequent changes required)
Change in wound condition (e.g. increase in exudate amt)
Dislodgement of dressing:
Suboptimal dressing application (e.g. selection of inappropriate dressing size, failure to clean periwound skin before applying dressing, insufficient fixation)
Exposure of dressing to mechanical forces (e.g. off-loading devices, patient mobility)
Patient interference w/ dressing
Dressing design deficiency:
Insufficient fluid handling capacity (absorption, retention and/or moisture vapor transmission)
Insufficient adhesion
Insufficient conformability (i.e. ability to conform to body contours & challenging anatomical wound locations)
4 weeks
Primary % of Participants With No Strike-through After 7 Days Wear Time at Day 7 and 21 Intact dressing after 7 days wear time, assessed @ Wk1 Day7 & Wk3 Day21 only. 1st week of dressing wear (Wks 1 & 3) is critical for start of wound healing.
Contributing factors to strike-through:
Saturation of dressing pad:
Inappropriate dressing type
Inappropriate dressing change freq. (i.e. more frequent changes required)
Change in wound condition (e.g. increase in exudate amt)
Dislodgement of dressing:
Suboptimal dressing application (e.g. selection of inappropriate dressing size, failure to clean periwound skin before applying dressing, insufficient fixation)
Exposure of dressing to mechanical forces (e.g. off-loading devices, patient mobility)
Patient interference w/ dressing
Dressing design deficiency:
Insufficient fluid handling capacity (absorption, retention and/or moisture vapor transmission)
Insufficient adhesion
Insufficient conformability (i.e. ability to conform to body contours & challenging anatomical wound locations)
Weeks 1 and 3
Secondary % of Participants With Equal or Better Outcomes on Local Wound and Skin Pain Before Dressing Removal With Five-layer Pain was measured by subjects' responses to Visual Analogue Scale (VAS) of 0-10 at intervals of 2, 0=no pain, 10=worst pain ever. 4 weeks
Secondary % of Participants With Equal or Better Outcomes on Local Wound and Skin Pain at Removal With Five-layer Pain was measured by subjects' responses to Visual Analogue Scale (VAS) of 0-10 at intervals of 2, 0=no pain, 10=worst pain ever. 4 weeks
Secondary % of Participants With Equal or Better Outcomes on Local Wound and Skin Pain Immediately After Dressing Removal With Five-layer Pain was measured by subjects' responses to Visual Analogue Scale (VAS) of 0-10 at intervals of 2, 0=no pain, 10=worst pain ever. 4 weeks
Secondary % of Participants With Equal or Better Outcomes With Five-layer in Evaluation of the Dressings Dressing evaluation was determined via visual observation by study clinicians and categorized by saturation level: Partly saturated, Mostly saturated, and Strike-through. 4 weeks
Secondary % of Participants With Equal or Better Outcomes With Five-Layer When Assessing Wound Granulation Wound granulation was measured by visual assessment and photodigital planimetry. Wound granulation were grouped into 6 categories: None, <25%, 25-49%, 50-74%, 75-99%, 100%. 4 weeks
Secondary % of Participants With Equal or Better Outcomes With Five-Layer When Assessing Wounds for Non-viable Tissue (Eschar, Fibrin Slough, Both) Non-viable tissue was determined by visual assessment and photodigital planimetry. Non-viable tissues were grouped into 5 categories: None, <25%, 25-49%, 50-74%, 75-100%. 4 weeks
Secondary Mean Difference in Score in SF12 Health-Related Quality-of-Life Questionnaire The SF-12 health survey consists of 12 questions that yield an eight-scale profile of functional health and well-being, and 2 component summary measures of physical and mental health. SF-12 scores range from 0 to 100 with lower scores indicate lower levels of health.
SF-12 questionnaire was administered at Screening/Baseline, Day 14, and Day 28 visits, and scored by a 3rd party vendor.
Results are mean differences between five-layer vs the comparator dressing and presented for each of the 8 health domains, and 2 component summary measures.
Negative scores indicate lower SF-12 scores (indicating lower levels of health) for the five-layer treatment group; positive scores indicate higher SF-12 scores for the five-layer group.
4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04497805 - Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers Phase 2
Withdrawn NCT03675269 - Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer: N/A
Completed NCT04624516 - Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence N/A
Not yet recruiting NCT06439667 - VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
Recruiting NCT05608187 - Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers Phase 2
Not yet recruiting NCT06278935 - Lifestyle Tailored Offloading for Diabetic Foot Ulcers N/A
Not yet recruiting NCT06437028 - Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers. N/A
Withdrawn NCT05024656 - AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers N/A
Terminated NCT02202668 - Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers N/A
Terminated NCT01966380 - Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Phase 2
Completed NCT01951768 - Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Phase 4
Completed NCT01657474 - Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers N/A
Active, not recruiting NCT00389636 - TheraGauzeā„¢ Alone and Regranex®Gel 0.01% Plus TheraGauzeā„¢ in the Treatment of Wagner Stage I Diabetic Foot Ulcers N/A
Completed NCT01181440 - Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers Phase 3
Enrolling by invitation NCT05888259 - Plantar Pressure Distribution in Diabetic Foot Ulcer N/A
Completed NCT04054804 - Digital Foot Check by Using the D-Foot, a New Software
Not yet recruiting NCT05877378 - Efficacy of PICO Single-use System in Chronic Ulcers N/A
Recruiting NCT06037369 - The Short Message-based Customized Standardized N/A
Completed NCT03312595 - Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) N/A
Recruiting NCT04564443 - A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot N/A